title: Socio-demographic and geographic variations in the utilization of hormone therapy in older women with breast cancer after Medicare Part-D coverage.
abstract: No study has previously reported the utilization and adherence to hormone therapy for Medicare Part-D beneficiaries with breast cancer. This study was conducted using the Surveillance, Epidemiology, and End Results-Medicare-linked data to assess socio-demographic, geographic, and other variations in the receipt of hormone therapy among patients with hormone receptor-positive breast cancer and to assess adherence to hormone therapy within 1-year follow-up. The percentage of patients who received hormone therapy was calculated and stratified by chemotherapy status (yes or no). Logistic regression models were performed to assess the variations associated with the use of selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and hormone therapy (SERMs or AIs). Of 25,128 women with hormone receptor-positive breast cancer in 2006-2009 who were enrolled in Medicare Part-D program, 70.8 % received hormone therapy, 22.2 % received SERM, and 56.9 % received AIs. Among those receiving chemotherapy, significant predictors of receiving hormone therapy included age, tumor stage, surgery type, radiation therapy; significant predictors of receiving SERM included race, year of diagnosis, and tumor stage; and significant predictors of receiving AI included age, race, socioeconomic status, geographic location, tumor stage, and radiation therapy. For those without receiving chemotherapy, most of the above factors were significant, but differed across each drug class. In conclusion, over two-thirds of hormone receptor-positive breast cancer patients received hormone therapy, and still 29.2 % of patients did not receive it. Tumor and clinical factors are the most significant predictors for the receipt of hormone therapy.
authors.affiliation: Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas School of Public Health, 1200 Pressler Street, RAS-E631, Houston, TX, 77030, USA.
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Xianglin L
authors.initials: XL
authors.lastname: Du
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D006278:Medicare; D012189:Retrospective Studies; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D014481:United States
chemical_list: D047072:Aromatase Inhibitors; D020845:Selective Estrogen Receptor Modulators
references.citation: Oncology (Williston Park). 2012 Jun;26(6):541-7, 550, 552 passim
references.pmid: 22870539
references.citation: Br J Cancer. 2011 May 10;104(10):1558-63
references.pmid: 21522148
references.citation: J Med Liban. 2009 Apr-Jun;57(2):124-9
references.pmid: 19623889
references.citation: Lancet Oncol. 2008 Jan;9(1):45-53
references.pmid: 18083636
references.citation: J Natl Compr Canc Netw. 2009 Feb;7(2):115-21
references.pmid: 19200415
references.citation: Br J Cancer. 2008 Dec 2;99(11):1763-8
references.pmid: 18985046
references.citation: Int J Clin Oncol. 2002 Oct;7(5):279-83
references.pmid: 12402060
references.citation: J Clin Oncol. 2005 Jan 20;23(3):619-29
references.pmid: 15545664
references.citation: Breast Cancer Res Treat. 2011 Sep;129(2):299-308
references.pmid: 21594663
references.citation: Cancer. 2007 Mar 1;109(5):832-9
references.pmid: 17243168
references.citation: Breast Cancer Res Treat. 2011 Apr;126(2):529-37
references.pmid: 20803066
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3445-51
references.pmid: 19451445
references.citation: Breast Cancer Res Treat. 2010 Aug;122(3):843-51
references.pmid: 20058066
references.citation: Am J Surg. 2008 Oct;196(4):500-4
references.pmid: 18809051
references.citation: N Engl J Med. 2005 Dec 29;353(26):2747-57
references.pmid: 16382061
references.citation: J Am Coll Surg. 2008 Jan;206(1):66-75
references.pmid: 18155570
references.citation: Br J Cancer. 2013 Apr 16;108(7):1515-24
references.pmid: 23519057
references.citation: J Clin Oncol. 2008 Feb 1;26(4):549-55
references.pmid: 18071188
references.citation: N Engl J Med. 2004 Sep 2;351(10):963-70
references.pmid: 15342804
references.citation: J Clin Oncol. 2005 Feb 1;23(4):783-91
references.pmid: 15681522
references.citation: Obstet Gynecol. 2003 Jan;101(1):114-22
references.pmid: 12517655